Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Liposomial IrinoTecan (Nal-IRI) With 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer "nITRo Trial

NCT03528785 is registered in ClinicalTrials.gov with Centro Ricerche Cliniche di Verona as lead sponsor.

NCT NCT03528785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03528785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Liposomial IrinoTecan (Nal-IRI) With 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer "nITRo Trial
Lead sponsor
Centro Ricerche Cliniche di Verona
Phase
Phase 2
Overall status
Unknown status
Start date
March 2, 2018
Completion date
November 1, 2022
Enrollment
67 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma